Abstract
Increasing evidence suggests that the elevation of β-amyloid (Aβ) peptides in the brain is central to the pathogenesis of Alzheimer's disease (AD). Our recent studies have demonstrated that nobiletin, a polymethoxylated flavone from citrus peels, enhances cAMP/protein kinase A/extracellular signal-regulated kinase/cAMP response element-binding protein signaling in cultured hippocampal neurons and ameliorates Aβ-induced memory impairment in AD model rats. For the first time, we report that this natural compound improves memory deficits in amyloid precursor protein (APP) transgenic mice that overexpress human APP695 harboring the double Swedish and London mutations [APP-SL 7-5 transgenic (Tg) mice]. Our enzyme-linked immunosorbent assay (ELISA) also showed that administration of nobiletin to the transgenic mice for 4 months markedly reduced quantity of guanidine-soluble Aβ1–40 and Aβ1–42 in the brain. Furthermore, consistent with the results of ELISA, by immunohistochemistry with anti-Aβ antibody, it was evidently shown that the administration of nobiletin decreased the Aβ burden and plaques in the hippocampus of APP-SL 7-5 Tg mice. These findings suggest that this natural compound has potential to become a novel drug for fundamental treatment of AD.
Footnotes
-
This work was supported by the Research Grant for Longevity Science (17C-1) from the Ministry of Health, Labor and Welfare. The current work was also supported in part by a grant from Takeda Science Foundation.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.108.140293.
-
ABBREVIATIONS: AD, Alzheimer's Disease; Aβ, β-amyloid; APP, amyloid precursor protein; CREB, cAMP response element-binding protein; ERK, extracellular signal-regulated kinase; NEP, neprilysin; Tg, transgenic; PKA, protein kinase A; ELISA, enzyme-linked immunosorbent assay; ANOVA, analysis of variance; MEK, mitogen-activated protein kinase kinase.
- Received April 22, 2008.
- Accepted June 5, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|